In summary, with the recent accumulation of evidence suggesting that SGLT2 inhibitors have CV and renal protective effects beyond glucose-lowering, the clinical use of SGLT2 inhibitors in patients with T2DM and established CVD could gain increased momentum. Here, SLC5A2 is linked to type 2 diabetes mellitus.